Madrigal Pharmaceuticals. has been granted a patent for methods to synthesize high-purity pyridazinone compounds as thyroid hormone analogs. The patent also includes a method for treating fatty liver disease using a specific compound at dosages between 20 mg and 100 mg daily. GlobalData’s report on Madrigal Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Madrigal Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Madrigal Pharmaceuticals's grant share as of June 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating fatty liver disease with pyridazinone compounds
The granted patent US11986481B2 outlines a method for treating fatty liver disease, specifically nonalcoholic steatohepatitis, through the administration of a compound known as 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, or its pharmaceutically acceptable salts. The treatment involves administering this compound at dosages ranging from 20 mg to 100 mg per day, with specific claims indicating that a daily single dose can be administered orally, potentially in tablet form. The patent also specifies that the compound should have a purity of at least 95%, with an additional claim for a higher purity of 98% or greater.
Furthermore, the patent details the formulation of a pharmaceutical composition that includes the aforementioned compound along with at least one excipient or carrier, ensuring that it is suitable for oral administration. The claims emphasize the versatility of the treatment method, allowing for variations in dosage and formulation while maintaining the focus on effectively addressing fatty liver disease. This patent represents a significant step in the development of targeted therapies for liver conditions, providing a framework for further research and potential clinical applications.
To know more about GlobalData’s detailed insights on Madrigal Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
